Trials / Completed
CompletedNCT01639703
Hepatic Xenetix-CT Perfusion
Diagnostic Contribution of XENETIX® CT PERFUSION in Pre-therapeutical Assessment of Hepatocellular Carcinoma
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 96 (actual)
- Sponsor
- Guerbet · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to prospectively determine the diagnostic value of Xenetix-CT perfusion for the discrimination between well-differentiated hepatocellular carcinomas (HCC) and poorly/moderately differentiated HCC, in histo-pathologically proven HCC, and with the aim to cover the entire liver.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Xenetix-CT perfusion imaging | Injection of 50 ml of Xenetix |
Timeline
- Start date
- 2012-04-01
- Primary completion
- 2014-10-01
- Completion
- 2014-10-01
- First posted
- 2012-07-13
- Last updated
- 2017-07-13
- Results posted
- 2017-07-13
Locations
5 sites across 4 countries: Austria, Germany, South Korea, Switzerland
Source: ClinicalTrials.gov record NCT01639703. Inclusion in this directory is not an endorsement.